Immunotherapy and radiation with nutrition support for esophageal cancer
This trial combines an immunotherapy drug (a PD-1 inhibitor) with radiation therapy and special nutrition drinks to treat esophageal cancer that cannot be removed with surgery. The goal is to see if this combination is safe and effective in helping patients live longer and feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have esophageal squamous cell carcinoma (a type of esophageal cancer) that is too advanced or early stage but cannot be surgically removed.
- You have not received chemotherapy or other systemic cancer treatments for this cancer before.
- Your tumor tests positive for a protein called PD-L1 (a marker that may predict response to immunotherapy).
- You are not able to receive standard chemotherapy with radiation at the same time (due to medical reasons or inability to tolerate it).
- You have at least one measurable tumor that can be seen on imaging scans.
- Your general health status is fair to good (ECOG score 0-2), and you are expected to live more than 3 months.
- Your blood counts and organ function (liver, kidneys, thyroid, heart) are within acceptable ranges as determined by standard lab tests.
- You have not had previous radiation to the chest area.
- You are not pregnant, breastfeeding, or have a history of certain serious infections (like hepatitis B, hepatitis C, or HIV).
- You have no active bleeding risk from the tumor, no fistulas, no other recent cancers, no organ transplants, and no severe allergies to the study drug.
- You have not had a live vaccine within 30 days before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding an “immunonutrition” nutrition plan to standard chemoradiation can improve outcomes for people with locally advanced, unresectable esophageal squamous cell cancer. It may help the treatment work better by supporting the immune system during therapy.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy followed by radiation therapy for advanced esophageal cancer that has spread. The goal is to see if this sequence can help shrink tumors and improve outcomes.
This trial tests different doses of radiation therapy combined with the immunotherapy drug sintilimab for people with locally advanced esophageal squamous cell carcinoma. The goal is to find the best radiation dose to improve treatment outcomes.
Hear when a new Locally Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.